Loading clinical trials...

A Clinical Trial of Cidabenamine Plus Azacitidine to Prevent Post-Transplant Progression in High-Risk Peripheral T-Cell Lymphoma | Clinical Trials | Clareo Health

RECRUITINGPHASE2/PHASE3

A Clinical Trial of Cidabenamine Plus Azacitidine to Prevent Post-Transplant Progression in High-Risk Peripheral T-Cell Lymphoma

A Clinical Study of Cidabenamine Combined With Azacitidine for Preventing Progression in High-Risk Peripheral T-Cell Lymphoma After Allogeneic Peripheral Blood Hematopoietic Stem Cell Transplantation

NCT07389616•Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

View on ClinicalTrials.gov

Summary

This study is a single-center, single-arm, prospective, phase II clinical trial designed to evaluate the efficacy and safety of Cidabenamine combined with Azacitidine as maintenance therapy following allogeneic peripheral blood hematopoietic stem cell transplantation in patients with high-risk peripheral T-cell lymphoma.During the screening/baseline period, informed consent will be obtained, and inclusion/exclusion criteria will be verified. The study plans to enroll 40 patients in each group. Enrolled patients will undergo demographic and medical history data collection, along with assessments including vital signs, physical examination, PET-CT, bone marrow aspiration smear, flow cytometry, lymphoid gene rearrangement, and bone marrow pathology.

Eligibility

Age

18 - 70 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Aged 18 to 70 years, male or female.
•2. Diagnosis of peripheral T-cell lymphoma (PTCL) according to the 2022 WHO criteria, including pathological subtypes such as PTCL not otherwise specified (PTCL-NOS), anaplastic large cell lymphoma (ALCL), and angioimmunoblastic T-cell lymphoma (AITL), but excluding hepatosplenic T-cell lymphoma; and meeting at least one of the following high-risk criteria:
•① Stable Disease (SD) at the time of transplantation;
•② Relapse after autologous hematopoietic stem cell transplantation (any disease status);
•③ ≥ Partial Response 1 (PR1).
•3. Underwent allogeneic peripheral blood hematopoietic stem cell transplantation for PTCL, with no restriction on donor type.
•4. Presence of complete donor chimerism in the bone marrow (T-cell chimerism \>95%).
•5. ECOG performance status of 0 or 1.
•6. Hematological function meeting the following requirements:
•① Absolute neutrophil count (ANC) ≥ 1.0 × 10⁹/L;
+2 more criteria

Exclusion Criteria

•1. Known hypersensitivity to hypomethylating agents or Cidabenamine.
•2. Presence of grade II or higher active acute Graft-versus-Host Disease (GVHD).
•3. Presence of moderate or more severe chronic GVHD.
•4. Any unstable systemic disease, including but not limited to: unstable angina, cerebrovascular accident or transient ischemic attack (within 3 months prior to screening), myocardial infarction (within 3 months prior to screening), congestive heart failure (New York Heart Association \[NYHA\] Class ≥ III), status post pacemaker implantation, severe arrhythmia requiring pharmacological treatment, hepatic, renal, or metabolic disease, or pulmonary hypertension.
•5. Active, uncontrolled infection, evidenced by any of the following: infection-related hemodynamic instability, worsening or new-onset infectious symptoms/signs, radiologic evidence of a new infectious focus, or persistent fever without localizing symptoms/signs where infection cannot be ruled out.
•6. Known HIV infection.
•7. Active Hepatitis B (HBV) or active Hepatitis C (HCV) requiring antiviral therapy.
•8. History of an autoimmune disease.
•9. Pregnant or lactating women.
•10. Concurrent participation in another interventional clinical trial and receiving other investigational drugs.

Locations (1)

Shanghai General hospital,Shanghai Jiao Tong University School of Medicine

Shanghai, Shanghai Municipality, China

Key Dates

Start Date

February 1, 2026

Primary Completion Date

February 1, 2028

Completion Date

August 1, 2029

Last Updated

February 5, 2026

Enrollment

ESTIMATED participants

Conditions

Peripheral T Cell Lymphoma

Interventions

Cidabenamine, Azacitidine

DRUG

Contacts

xianmin song, MD

CONTACT

+862163240090 shongxm@139.com

Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma

NCT07356245

T-cell LymphomaGraft Versus Host Disease+6 more

View study

RECRUITING

T Cell Lymphoma -Stratified Therapy After Response to First-line Treatment-CR

NCT07353840

Peripheral T Cell Lymphoma

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 5, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Clinical Trial of Cidabenamine Plus Azacitidine to Prevent Post-Transplant Progression in High-Risk Peripheral T-Cell Lymphoma

Inclusion Criteria

Exclusion Criteria

Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma

T Cell Lymphoma -Stratified Therapy After Response to First-line Treatment-CR

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL

CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma

Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma